Showing results (21-30 of 46) with videos related to
Sort By:
Pageof 5
Age and Ageing|June 9, 2021
Enrolment of older adults with cancer in early phase clinical trials-an observational study on the experience in the north west of EnglandFabio Gomes, Tine Descamps, Jessica Lowe, et al.Journal for Immunotherapy of Cancer|January 12, 2026
Cell therapy in sarcoma: current landscape and future directionsTaha Koray Sahin, Theodora Germetaki, Deniz Can Guven, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 4, 2009
Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alphaRobert E Hawkins, Catriona Macdermott, Alaaeldin Shablak, et al.The Oncologist|July 12, 2019
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced CancerNadina Tinsley, Cong Zhou, Grace Tan, et al.Cancer Medicine|October 9, 2025
Patient and Clinician Perspectives on the Communication of Genomic Results in Cancer CareEleanor Johnston, Zoulikha Zair, Leanna Goodwin, et al.Cancers|June 2, 2021
Discovery and Evaluation of Protein Biomarkers as a Signature of Wellness in Late-Stage Cancer Patients in Early Phase Clinical TrialsBethany Geary, Erin Peat, Sarah Dransfield, et al.Cancer Chemotherapy and Pharmacology|June 20, 2020
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumorsMats Någård, Mei-Lin Ah-See, Karen So, et al.Cancer Immunology, Immunotherapy : CII|June 18, 2026
A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignanciesPiotr Rutkowski, Dariusz M Kowalski, Victor Moreno, et al.Targeted Oncology|August 12, 2017
A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric CancersBernard Escudier, Sandrine Faivre, Eric Van Cutsem, et al.Cell Reports. Medicine|March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignanciesJuanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.Pageof 5